Thorough workup algorithm is essential for lung screening trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 12
Volume 16
Issue 12

The lack of an effective, detailed workup algorithm for positive results in multicenter lung cancer screening trials leads to a lower cancer yield from invasive procedures and later diagnoses for participants

CHICAGO—The lack of an effective, detailed workup algorithm for positive results in multicenter lung cancer screening trials leads to a lower cancer yield from invasive procedures and later diagnoses for participants, according to a new study presented at the 2007 RSNA meeting.

During a scientific session, David Yankelevitz, MD, investigator in the New York Early Lung Cancer Action Program (NY-ELCAP), compared workup algorithms and results for the New York trial and the Lung Screening Study (LSS), the pilot study of the ongoing NCI-sponsored National Lung Screening Trial.

In NY-ELCAP, with 6,295 participants at risk for lung cancer, a very detailed algorithm was used following diagnosis with low-dose spiral CT. In contrast, the LSS, which randomized patients to spiral CT or chest x-ray, did not specify an algorithm, as organizers determined that they could not dictate medical practice. Dr. Yankelevitz's study analyzed results for 1,586 participants in the LSS's CT arm.

Participants in the two studies were at similar risk for lung cancer, had the same initial baseline test, and had an annual repeat test.

In the NY-ELCAP, 92% of invasive procedures performed after baseline screening resulted in cancer detection and 92% were also positive when performed as a result of the annual repeat CT exam.

By comparison, in LSS participants, 57% of invasive procedures turned up cancer on baseline screening and 44% on the annual repeat exam.

At baseline in both studies, cancers were detected at larger sizes, as expected. However, the size of cancer detected at annual repeat differed markedly, as 55% were smaller than 10 mm in the NY-ELCAP study, whereas only 13% were smaller than 10 mm for LSS.

The researchers also noted that the percent of cancers detected at stage I was higher in the New York study relative to the LSS.

Patient outcomes were better in the NY-ELCAP study, most likely due to differences in the workup algorithms, according to Dr. Yankelevitz, professor of radiology at Weill Cornell Medical College.

"This study shows the benefit of workup algorithms in screening protocols. Screening is not just about the initial test; it includes the baseline screening test all the way thorough diagnostics, including pathology," he said in an interview after the RSNA session.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content